Kornimate/medical-research-clean huggingface dataset:
to study the association among labor pain and physical parameters in laboring pregnant women

Conditions: Labor Pain

Summary: analysis of monitored clinically parameters during the course of labor is a seldom studied area in taiwan and worldwide. important monitored parameters include, fetal heartbeat, uterine contractions, oxygen saturation and blood pressure, among others.1 during labor, uterine contractions can cause pain.3 this pain may be measured using a visual analogue scale (vas).2 the pain from uterine contractions promotes the release of hormones including cortisol which can cause decreased or irregular contractions and possibly prolong labor.3 this study aims to study the association between monitored clinical parameters and pain in women in taiwan during labor in order to increase the understanding to safe childbirth.

this is a prospective, observational study to measure and collect and physical parameters from females at least 20 years of age in the labor room. collection of measurements and physical parameters will begin when the subject enrolls in the study. besides, ecg and spo2 will be recorded continuously until the end of the study period. in addition, uterus contraction cycle and fetal heart beat will be recorded during the study period based on standard of care in the labor room. pain will be recorded on a visual analogue scale (vas) at baseline and when the caregiver perceives that there is a change in the subject's pain status until the end of the study period. the time of each assessment of pain on vas should be recorded. subjects will be withdrawn from the study if they have a cesarean section or any complication during labor in the opinion of the investigator. subject participation in the study will end when eight hours have elapsed since baseline, the subject leaves the labor room or the subject delivers the baby.

Eligibility criteria:
inclusion criteria: 1. female at least 20 years of age. 2. have a course of labor that is \> 4 hours. 3. american society of anesthesiologists physical status (asa ps) classification of class i-ii. 4. clinical records of the subject are complete in the opinion of the investigator. exclusion criteria: 1. subject has any condition, which in the opinion of the investigator precludes the subject's participation in the study.
citocoline for treatment in fragile x-associated tremor/ataxia syndrome

Conditions: Fragile X Tremor/Ataxia Syndrome

Summary: the objective of this study is to determine if citocoline is effective for balance abnormalities and to stabilize cognitive decline in patients with fragile x-associated tremor ataxia syndrome. the study will test 1000mg twice daily of citocoline for 12 months in an open label pilot study, with study visits at baseline, 3, 6, and 12 months.

the purpose of this study was to determine if citicoline was safe for the treatment of tremor and balance abnormalities and to stabilize cognitive decline in patients with fragile x-associated tremor ataxia syndrome. ten participants with diagnosed fxtas were administered 1000 mg of citicoline once daily for 12 months. outcome measures and neurological examination were performed at baseline, 3 months, 6 months, and 12 months. the primary outcome was safety. secondary outcomes included change in fxtas rating scale score, a battery of neuropsychological tests, an instrumented timed up and go test, computerized dynamic posturography, 9-hole pegboard test, and balance confidence and psychiatric symptom questionnaires.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of fxtas * serum creatine kinase, complete metabolic panel, complete blood count, liver function tests, renal function tests, platelets and ekg are within normal limits exclusion criteria: * legal incapacity or limited legal capacity * presence of severe renal disease (bun 50% greater than normal or creatinine clearance \<60 ml/min) or hepatic disease. * abnormal creatine kinase and/or platelet count in the past 6 months (as determined by lab reports obtained from primary care physicians or conducted at baseline). * women of childbearing potential who are pregnant at the time of screening or who will not use adequate protection during participation of the study. * allergy/sensitivity to the drug of its formulations. * concurrent participation in another clinical study. * active substance use or dependence. * serious illness (requiring systematic treatment/or hospitalization) until the subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 60 days prior to study entry. * inability or unwillingness of the subject or legal guardian/representative to give written informed consent.
a study for patients with erectile dysfunction to test whether tadalafil taken once a day can better improve psychological outcomes.

Conditions: Erectile Dysfunction

Summary: the primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ed).


Eligibility criteria:
inclusion criteria: * history of erectile dysfunction (ed). * have had satisfactory response to tadalafil, sildenafil citrate, or vardenafil hcl for a period of at least 6 months and expect frequent use (at least one dose per week, on average) when administered as needed. * have never used tadalafil 5 mg or 2.5 mg once a day therapy. * anticipate having the same adult female sexual partner willing to participate during the study. * agree to make at least four sexual intercourse attempts during the first four weeks of the study. * agree not to use any other treatment for ed (even herbal treatments) during the study. * agree to follow the directions given by the study doctor and staff about using the study drug. exclusion criteria: * have any other primary sexual disorders present or penile deformity. * have history of radical prostatectomy or penile implant. * have problems with your kidneys, liver, or nervous system. * have uncontrolled diabetes, as measured by a blood test for haemoglobin a1c greater than a value of 11%. * are being treated for heart disease with any drug that is called a nitrate (for example, nitroglycerin). * have chest pain (called unstable angina or angina) that requires treatment. * have heart disease that causes symptoms after you exert yourself. * have had any of the following in the past 90 days: heart attack, also known as a myocardial infarction (mi); heart bypass surgery (called coronary artery bypass graft surgery); had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention). * have a history of loss of vision in one eye because of nonarteritic anterior ischemic optic neuropathy (naion). * have retinitis pigmentosa. * have history of human immunodeficiency virus (hiv). * have very high or very low blood pressure (your study doctor will discuss the limits with you). * have had a stroke or a significant injury to your brain or spinal cord within the last 6 months. * have rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption lactose intolerance. * have a scheduled or planned surgery requiring anaesthesia during the course of the study. * have a scheduled cataract surgery during the curse of the study.
comparison of the time to recurrence between ranibizumab and aflibercept

Conditions: The Injection Burden

Summary: the investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with amd.


Eligibility criteria:
inclusion criteria: * they must have had bcva better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept. exclusion criteria: * patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.
mirror therapy and treadmill training for patients with chronic stroke

Conditions: Stroke

Summary: this is a pilot randomised controlled trial investigating a combination of mirror therapy and treadmill training for the rehabilitation of lower limb impairment following a stroke. this study has been conducted as part of a phd qualification at the institute of technology sligo in ireland with all therapy sessions taking place at the institute. the study was conducted in conjunction with sligo university hospital and it attained ethical approval through the relevant university hospital ethics committee.

the study necessitated patients with chronic stroke to walk on a treadmill while viewing a reflection of their non-affected limb in a mirror. there was also a placebo group and these patients walked on the treadmill and viewed a mirror in an altered position. patients were referred through hospital health professionals. prior to trial commencement all participants were given comprehensive trial information and provided signed written informed consent. a total of 30 participants were recruited. patients attended the study for 30 minutes per day, three days per week, for four weeks. patients received outcome assessment prior to the beginning of the intervention, directly after it and at three month followup assessment. all assessments were carried out by a chartered physiotherapist specialising in stroke rehabilitation. patients were assessed using established outcome measures for lower limb motor function, muscle tone, walking speed and endurance.

Eligibility criteria:
inclusion criteria: * chronic stroke (greater than or equal to 6 months post stroke) with lower limb heimiparesis. * ambulatory with/without walking aid. * discharged from formal rehabilitation. * a mini mental state examination \>/= 24. exclusion criteria: * younger than 18 years * any additional illness that may prevent treadmill walking * a mini mental state examination \< 24.
developing and piloting a multi-component technology-based care intervention to address patient symptoms and caregiver burden in home hospice. phase 1.

Conditions: Home Hospice

Summary: with the growth of hospice, older adults have the opportunity to receive home-based care aimed at reducing suffering and focusing on quality of life at the end of life. while use of technology and educational videos has yet to be fully developed, structured, and evaluated in home hospice care, it has shown promise to improve care in other settings. therefore, this study aims to develop and evaluate a multi-component technology-based care intervention, i.e., improving home hospice management of end of life issues through technology (i-home), that focuses on assessing and addressing patient symptoms and caregiver burden in the home hospice setting through synchronous live video visits and educational videos. the aim of the first phase of the project is to employ an iterative user-centered design process to develop i-home for home hospice patients and their caregivers prior to implementation.


Eligibility criteria:
inclusion criteria: * home hospice providers (n=10) and family caregivers (n=10) must be english speaking, 18 years of age or older, not blind, and either providing or receiving home hospice care. home hospice patients (n=10) must be english speaking, 65 years of age or older, not blind, and enrolled in home hospice care. exclusion criteria: * patients with a terminal diagnosis of dementia or patients who have cognitive impairment and unable to sign a written informed consent will be excluded.
switching individuals in treatment for opioid use disorder who smoke cigarettes to the srec

Conditions: Electronic Cigarette Use

Summary: the goal of this study is to conduct a pilot randomized waitlist-controlled trial to assess the feasibility, acceptability, and preliminary effects of substituting the nida standardized research e-cigarette (srec) for combusted cigarettes in moud-tud who are not ready to quit smoking. a waitlist controlled rct using a mixed-methods sequential explanatory design will investigate the impact of srec provision on: 1) tobacco use behavior (e.g., cigarettes per day \[primary outcome\], srec use), 2) biomarkers (e.g., carbon monoxide, anabasine), 3) cigarette dependence and withdrawal, and 4) short-term health effects and tolerability (e.g., respiratory symptoms, substance use). in the proposed rct, n=40 adults stable on moud with buprenorphine who report daily smoking recruited from mgh primary care practices will be randomly assigned to receive the srec for 8 weeks, either immediately (isrec), or after an 8-week delay (waitlist control \[wlc\]). they will be followed an additional 4 weeks after srec provision ends (to 12 weeks in isrec and 20 weeks in wlc).


Eligibility criteria:
inclusion criteria: * 18 years of age * report daily cigarette smoking (\>=10 cigarettes per day in the past week) * not ready to quit smoking (not planning to quit in the next 30 days) * willing to try e-cigarettes * in stable buprenorphine (bup) treatment for opioid use disorder at an massachusetts general hospital-affiliated primary care clinic (in treatment for \>=3 months without changes in bup dose in the past 2 weeks and planning to remain on current bup treatment for \>=3 months). exclusion criteria: * pregnant or breastfeeding * using non-cigarette nicotine or tobacco products (e.g., e-cigarettes, cigarillos) recently (\>3 days in past 30 days) * report past 30-day use of behavioral or pharmacologic smoking cessation aids * deemed inappropriate for participation by their oud provider * have an unstable psychiatric (e.g., past month suicidal ideation, active psychosis) or medical condition (e.g., life expectancy \<1 year).
the effect of different exercise types on migraine frequency in individuals with migraine

Conditions: Migraine; Chronic Migraine

Summary: the purpose of this study is to evaluate and compare the effect of different exercise types and combinations on migraine attacks in patients with migraine.


Eligibility criteria:
inclusion criteria: * a diagnosis of migraine confirmed by a specialist neurologist according to international classification of headache disorders, 3rd version(ichd-3) * diagnosed as chronic migraine at the time of initial diagnosis (may have turned into episodic migraine under preventive treatment) * at least 5 migraine attack/month in baseline diary * no obstacle to exercise in the evaluation made with physical examination and ecg * diagnosed with migraine for at least 12 months * between the ages of 18-50 exclusion criteria: * exercising regularly in the last 6 months * presence of concomitant internal and neurological diseases * anti-psychotic drug use * drug, alcohol addiction * pregnancy, breastfeeding * patients who cannot reach the targeted exercise level

Keywords: headache exercise resistance exercises aerobic exercise
impact of tdcs on cerebral autoregulation

Conditions: Cerebral Microangiopathy; CADASIL; Migraine With Aura; ICA Stenosis

Summary: the aim of the study is to investigate whether there is a polarity-specific influence of tdcs on cerebral vasomotor reactivity monitored by transcranial doppler sonography.


Eligibility criteria:
inclusion criteria: 1. severe cerebral microangiopathy 2. notch3 carrier 3. migraine with aura (ihs classification ichd-ii) 4. stenosis \>80%, ecst-criteria exclusion criteria: * seizure disorder * history of severe alcohol or drug abuse, psychiatric illness like severe depression, poor motivational capacity * dementia (1+2) history of stroke in past 3 months (3) migraine prophylaxis (4) contralateral stenosis \>50%,
native kidney denervation in patients with end stage renal disease

Conditions: End Stage Renal Disease

Summary: to investigate the utility of renal denervation in the treatment of patients with end stage renal disease (esrd).


Eligibility criteria:
inclusion criteria: * adult \>= 18 years of age * end stage renal disease, undergoing concurrent dialysis treatment * poorly controlled blood pressure on at least 2 antihypertensive drugs * agrees to have the study procedure(s) performed and additional procedures and evaluations, including interventions and follow up visits * competent and willing to provide written, informed consent to participate in this clinical study. exclusion criteria: * renal arterial abnormalities * myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within six (6) months * hemodynamically significant valvular heart disease * implantable cardioverter defibrillator (icd) or pacemaker * respiratory support. * pregnant, nursing or planning to be pregnant * other
the real world study of btk inhibitor in the treatment of chronic lymphocytic leukemia in china

Conditions: CLL

Summary: this is a multicenter, retrospective real-world study of zanubrutinib in the treatment of chronic lymphocytic leukemia in china


Eligibility criteria:
inclusion criteria: 1. patients aged ≥18 years old 2. must have a confirmed diagnosis of chronic lymphocytic leukemia (cll) requiring treatment (iwcll \[international workshop on chronic lymphocytic leukemia\] criteria)； 3. treatment-naïve or refractory recurrence cll patients who were initiated on btk inhibitor; 4. prior or current use of btk inhibitor for ≥3 months 5. at least one follow-up was recorded during btk inhibitor treatment
transthecal metacarpal block versus traditional digital block for painful finger procedures in children

Conditions: Finger Injuries

Summary: the purpose of this study is to determine if the transthecal metacarpal block is superior to the traditional digital block for regional digital anesthesia in children.

background: finger injuries and infections are common presenting problems in the pediatric emergency department. a traditional digital block, requiring at least two injections of anesthetic, is the traditional method of regional anesthesia for many finger procedures. digital blocks can sometimes be difficult to administer and assess for effectiveness especially in children. a newer procedure, the transthecal metacarpal block, may be easier to administer, and more effective with one injection. objective: to determine if the transthecal metacarpal block (mcb) provides superior digit anesthesia in children requiring painful finger procedures as compared to the traditional digital block (tdb). methods: a randomized clinical trial comparing the mcb to the tdb will be conducted in an urban, tertiary care pediatric emergency department. children \<18 years of age, presenting to the emergency department with a finger injury or infection, which requires regional anesthesia for repair will be screened for eligibility. eligible patients, with appropriate consent will be randomized to receive either the mcb or tdb with 1% lidocaine. the primary outcome, success of the block will be assessed using pinprick testing after a standardized wait time. secondary outcomes including pain with the block and repair, repairing physician satisfaction, and short-term complications will also be assessed. implications: finding successful methods of anesthesia and pain control are paramount in the pediatric emergency department. in addition, using a type of digital block which is easy to administer, successful, and requires only one injection would give physicians confidence to treat finger injuries in children with regional anesthesia and possibly avoid procedural sedation in some cases. to date, no studies have been published on the efficacy of digital blocks in children. this study will also serve to give baseline success rates for both types of digital blocks.

Eligibility criteria:
inclusion criteria: * age \<18 years * greater than 10 kg in weight * have finger injuries or infections that will require digital regional anesthesia * require only local anesthesia for the repair * english speaking exclusion criteria: * have previous participation in this study * need procedural sedation at the onset of the repair * have allergy to lidocaine or amide-type local anesthetics * have infection at the sites of block injection * have known coagulopathy

Keywords: digital block regional anesthesia finger repair fingers anesthesia, conduction
lumason® infusion vs. bolus administrations

Conditions: Heart Diseases

Summary: a phase iii study designed as a randomized, within-patient comparison of continuous infusion of diluted lumason® versus the bolus administration of undiluted lumason® for degree of lvo and assessment of lv ebd (co-primary endpoints).

this is a phase iii study designed as a randomized, within-patient comparison of continuous infusion of diluted lumason® versus the bolus administration of undiluted lumason® for degree of lvo and assessment of lv ebd (co-primary endpoints). the study will enroll patients with suboptimal lv ebd defined as ≥2 adjacent segments in any apical view that cannot be visualized at pre-contrast echocardiogram.

Eligibility criteria:
inclusion criteria: * are at least 18-years old; * have suboptimal lv ebd, defined as ≥2 adjacent segments in any apical view that cannot be visualized, at pre-contrast echocardiogram; * provide their written informed consent and are willing to comply with protocol requirements. exclusion criteria: * patient has severe congestive heart failure (class iv according to the classification of the new york heart association); * patient has uncontrolled angina (i.e., uncontrolled on medication); * patient had a recent myocardial infarction (within the last 3 days and not stabilized); * patient has severe arrhythmia, that in the opinion of the investigator, would interfere with the study conduct; * patient has severe pulmonary hypertension, that in the opinion of the investigator, would interfere with the study conduct; * patient had been treated with any other contrast medium, either intravascular or orally, within 48 hours prior to the first administration; * has any known allergy to one or more of the ingredients of the investigational product; * is pregnant or lactating. exclude the possibility of pregnancy by: testing on site (serum or urine βhcg) prior to the start of investigational product administration; surgical history (e.g., tubal ligation or hysterectomy); post-menopausal with a minimum 1 year without menses; * has previously entered the study or have received any other investigational drug within 30 days prior to admission in this study; * is determined by the investigator that the patient is clinically unsuitable for the study.